[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018, Forecast to 2023

August 2018 | 136 pages | ID: G9DE5388C61EN
GlobalInfoResearch

US$ 4,880.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

Scope of the Report:

This report focuses on the Drugs for Vulvovaginal Candidiasis in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.
The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.
Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.
The worldwide market for Drugs for Vulvovaginal Candidiasis is expected to grow at a CAGR of roughly 2.1% over the next five years, will reach 870 million US$ in 2023, from 770 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
  • Bayer
  • Perrigo
  • J & J
  • Pfizer
  • Bristol-Myers Squibb
  • Effik
  • Teva
  • Sanofi
  • Cisen Pharmaceutical
  • Kingyork Group
Market Segment by Regions, regional analysis covers
  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia and Italy)
  • Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • South America (Brazil, Argentina, Colombia etc.)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
  • Cream
  • Pessary
  • Other
Market Segment by Applications, can be divided into
  • Hospital & Clinic
  • Pharmacy
There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
1 MARKET OVERVIEW

1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
  1.2.1 Cream
  1.2.2 Pessary
  1.2.3 Other
1.3 Market Analysis by Applications
  1.3.1 Hospital & Clinic
  1.3.2 Pharmacy
1.4 Market Analysis by Regions
  1.4.1 North America (United States, Canada and Mexico)
    1.4.1.1 United States Market States and Outlook (2013-2023)
    1.4.1.2 Canada Market States and Outlook (2013-2023)
    1.4.1.3 Mexico Market States and Outlook (2013-2023)
  1.4.2 Europe (Germany, France, UK, Russia and Italy)
    1.4.2.1 Germany Market States and Outlook (2013-2023)
    1.4.2.2 France Market States and Outlook (2013-2023)
    1.4.2.3 UK Market States and Outlook (2013-2023)
    1.4.2.4 Russia Market States and Outlook (2013-2023)
    1.4.2.5 Italy Market States and Outlook (2013-2023)
  1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    1.4.3.1 China Market States and Outlook (2013-2023)
    1.4.3.2 Japan Market States and Outlook (2013-2023)
    1.4.3.3 Korea Market States and Outlook (2013-2023)
    1.4.3.4 India Market States and Outlook (2013-2023)
    1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
  1.4.4 South America, Middle East and Africa
    1.4.4.1 Brazil Market States and Outlook (2013-2023)
    1.4.4.2 Egypt Market States and Outlook (2013-2023)
    1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
    1.4.4.4 South Africa Market States and Outlook (2013-2023)
    1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
  1.5.1 Market Opportunities
  1.5.2 Market Risk
  1.5.3 Market Driving Force

2 MANUFACTURERS PROFILES

2.1 Bayer
  2.1.1 Business Overview
    2.1.1.1 Bayer Description
    2.1.1.2 Bayer Headquarter, Main Business and Finance Overview
  2.1.2 Bayer Drugs for Vulvovaginal Candidiasis Product Introduction
    2.1.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.1.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.1.3.1 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.1.3.2 Global Bayer Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.2 Perrigo
  2.2.1 Business Overview
    2.2.1.1 Perrigo Description
    2.2.1.2 Perrigo Headquarter, Main Business and Finance Overview
  2.2.2 Perrigo Drugs for Vulvovaginal Candidiasis Product Introduction
    2.2.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.2.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.2.3.1 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.2.3.2 Global Perrigo Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.3 J & J
  2.3.1 Business Overview
    2.3.1.1 J & J Description
    2.3.1.2 J & J Headquarter, Main Business and Finance Overview
  2.3.2 J & J Drugs for Vulvovaginal Candidiasis Product Introduction
    2.3.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.3.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.3.3.1 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.3.3.2 Global J & J Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.4 Pfizer
  2.4.1 Business Overview
    2.4.1.1 Pfizer Description
    2.4.1.2 Pfizer Headquarter, Main Business and Finance Overview
  2.4.2 Pfizer Drugs for Vulvovaginal Candidiasis Product Introduction
    2.4.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.4.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.4.3.1 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.4.3.2 Global Pfizer Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.5 Bristol-Myers Squibb
  2.5.1 Business Overview
    2.5.1.1 Bristol-Myers Squibb Description
    2.5.1.2 Bristol-Myers Squibb Headquarter, Main Business and Finance Overview
  2.5.2 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Introduction
    2.5.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.5.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.5.3.1 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.5.3.2 Global Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.6 Effik
  2.6.1 Business Overview
    2.6.1.1 Effik Description
    2.6.1.2 Effik Headquarter, Main Business and Finance Overview
  2.6.2 Effik Drugs for Vulvovaginal Candidiasis Product Introduction
    2.6.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.6.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.6.3.1 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.6.3.2 Global Effik Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.7 Teva
  2.7.1 Business Overview
    2.7.1.1 Teva Description
    2.7.1.2 Teva Headquarter, Main Business and Finance Overview
  2.7.2 Teva Drugs for Vulvovaginal Candidiasis Product Introduction
    2.7.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.7.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.7.3.1 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.7.3.2 Global Teva Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.8 Sanofi
  2.8.1 Business Overview
    2.8.1.1 Sanofi Description
    2.8.1.2 Sanofi Headquarter, Main Business and Finance Overview
  2.8.2 Sanofi Drugs for Vulvovaginal Candidiasis Product Introduction
    2.8.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.8.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.8.3.1 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.8.3.2 Global Sanofi Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.9 Cisen Pharmaceutical
  2.9.1 Business Overview
    2.9.1.1 Cisen Pharmaceutical Description
    2.9.1.2 Cisen Pharmaceutical Headquarter, Main Business and Finance Overview
  2.9.2 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Introduction
    2.9.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.9.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.9.3.1 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.9.3.2 Global Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Market Share in 2017
2.10 Kingyork Group
  2.10.1 Business Overview
    2.10.1.1 Kingyork Group Description
    2.10.1.2 Kingyork Group Headquarter, Main Business and Finance Overview
  2.10.2 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Introduction
    2.10.2.1 Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
    2.10.2.2 Drugs for Vulvovaginal Candidiasis Product Information
  2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.10.3.1 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    2.10.3.2 Global Kingyork Group Drugs for Vulvovaginal Candidiasis Market Share in 2017

3 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET COMPETITION, BY MANUFACTURER

3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
  3.4.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
  3.4.2 Top 5 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share in 2017
3.5 Market Competition Trend

4 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET ANALYSIS BY REGIONS

4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
  4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
  4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
4.2 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2013-2018)

5 NORTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
  5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
  5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
  5.1.3 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  5.1.4 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  5.1.5 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.2 North America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
  5.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
  5.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
5.3 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  5.3.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
  5.3.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
5.4 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
  5.4.1 North America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
  5.4.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)

6 EUROPE DRUGS FOR VULVOVAGINAL CANDIDIASIS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
  6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
  6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
  6.1.3 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  6.1.4 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  6.1.5 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  6.1.6 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  6.1.7 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.2 Europe Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
  6.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
  6.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
6.3 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  6.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
  6.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
  6.4.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
  6.4.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)

7 ASIA-PACIFIC DRUGS FOR VULVOVAGINAL CANDIDIASIS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
  7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
  7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
  7.1.3 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  7.1.4 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  7.1.5 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  7.1.6 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  7.1.7 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
  7.2.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
  7.2.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  7.3.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
  7.3.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
  7.4.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
  7.4.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)

8 SOUTH AMERICA DRUGS FOR VULVOVAGINAL CANDIDIASIS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
  8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
  8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
  8.1.3 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  8.1.4 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  8.1.5 Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.2 South America Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
  8.2.1 South America Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
  8.2.2 South America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
8.3 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  8.3.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
  8.3.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
8.4 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
  8.4.1 South America Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
  8.4.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)

9 MIDDLE EAST AND AFRICA DRUGS FOR VULVOVAGINAL CANDIDIASIS BY COUNTRIES, TYPE, APPLICATION AND MANUFACTURERS

9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
  9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
  9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
  9.1.3 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  9.1.4 UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  9.1.5 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  9.1.6 Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
  9.1.7 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Revenue (Value) by Manufacturers (2016-2017)
  9.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2017)
  9.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Type (2013-2018)
  9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Application (2013-2018)
  9.4.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Sales Share by Application (2013-2018)
  9.4.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Revenue Share by Application (2013-2018)

10 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET SEGMENT BY TYPE

10.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
  10.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
  10.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
10.2 Cream Sales Growth and Price
  10.2.1 Global Cream Sales Growth (2013-2018)
  10.2.2 Global Cream Price (2013-2018)
10.3 Pessary Sales Growth and Price
  10.3.1 Global Pessary Sales Growth (2013-2018)
  10.3.2 Global Pessary Price (2013-2018)
10.4 Other Sales Growth and Price
  10.4.1 Global Other Sales Growth (2013-2018)
  10.4.2 Global Other Price (2013-2018)

11 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET SEGMENT BY APPLICATION

11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
11.2 Hospital & Clinic Sales Growth (2013-2018)
11.3 Pharmacy Sales Growth (2013-2018)

12 DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET FORECAST (2018-2023)

12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2018-2023)
  12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
  12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
  12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
  12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
  12.2.5 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
  12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
  12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
  12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
  12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)

13 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS

13.1 Sales Channel
  13.1.1 Direct Marketing
  13.1.2 Indirect Marketing
  13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers

14 RESEARCH FINDINGS AND CONCLUSION

15 APPENDIX

15.1 Methodology
15.2 Data Source
LIST OF TABLES AND FIGURES

Figure Drugs for Vulvovaginal Candidiasis Picture
Table Product Specifications of Drugs for Vulvovaginal Candidiasis
Figure Global Drugs for Vulvovaginal Candidiasis CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Drugs for Vulvovaginal Candidiasis CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Types in 2017
Figure Cream Picture
Table Major Manufacturers of Cream
Figure Pessary Picture
Table Major Manufacturers of Pessary
Figure Other Picture
Table Major Manufacturers of Other
Figure Drugs for Vulvovaginal Candidiasis Sales Market Share by Applications in 2017
Figure Hospital & Clinic Picture
Figure Pharmacy Picture
Figure United States Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure France Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure UK Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure China Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure India Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Table Bayer Headquarter, Established, Main Business and Finance Overview (2017)
Table Bayer Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Bayer Drugs for Vulvovaginal Candidiasis Product
Table Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bayer Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Bayer Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Perrigo Headquarter, Established, Main Business and Finance Overview (2017)
Table Perrigo Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Perrigo Drugs for Vulvovaginal Candidiasis Product
Table Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Perrigo Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Perrigo Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table J & J Headquarter, Established, Main Business and Finance Overview (2017)
Table J & J Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table J & J Drugs for Vulvovaginal Candidiasis Product
Table J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global J & J Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global J & J Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Pfizer Headquarter, Established, Main Business and Finance Overview (2017)
Table Pfizer Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Pfizer Drugs for Vulvovaginal Candidiasis Product
Table Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Pfizer Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Pfizer Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Bristol-Myers Squibb Headquarter, Established, Main Business and Finance Overview (2017)
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Effik Headquarter, Established, Main Business and Finance Overview (2017)
Table Effik Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Effik Drugs for Vulvovaginal Candidiasis Product
Table Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Effik Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Effik Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Teva Headquarter, Established, Main Business and Finance Overview (2017)
Table Teva Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Teva Drugs for Vulvovaginal Candidiasis Product
Table Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Teva Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Teva Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Sanofi Headquarter, Established, Main Business and Finance Overview (2017)
Table Sanofi Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Sanofi Drugs for Vulvovaginal Candidiasis Product
Table Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sanofi Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Sanofi Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Cisen Pharmaceutical Headquarter, Established, Main Business and Finance Overview (2017)
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Kingyork Group Headquarter, Established, Main Business and Finance Overview (2017)
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Production Bases, Sales Regions and Major Competitors
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Product
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Kingyork Group Drugs for Vulvovaginal Candidiasis Sales Market Share in 2017
Figure Global Kingyork Group Drugs for Vulvovaginal Candidiasis Revenue Market Share in 2017
Table Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2017)
Figure Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Global Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2013
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2017
Figure North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table North America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries 2017
Figure China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table South America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Application (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2013-2018)
Figure Global Cream Sales Growth (2013-2018)
Figure Global Cream Price (2013-2018)
Figure Global Pessary Sales Growth (2013-2018)
Figure Global Pessary Price (2013-2018)
Figure Global Other Sales Growth (2013-2018)
Figure Global Other Price (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2013-2018)
Figure Global Hospital & Clinic Sales Growth (2013-2018)
Figure Global Pharmacy Sales Growth (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Regions (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Regions (2018-2023)
Figure North America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Europe Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Asia-Pacific Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure South America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Middle East and Africa Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List


More Publications